Developing Novel Clinical Endpoints to Improve Clinical Trials Design & Population Enrichment for Retinal Disease & Pipeline Development
Time: 8:30 am
day: Conference Day One
Details:
- Uncovering novel clinical trial endpoints for Dry AMD, Wet AMD and other retinal vascular diseases
- Reviewing the journey of emerging GA endpoints from being non-measurable to achieving FDA approval
- Utilizing biomarkers for clinical trial enrichment to allow for more efficient clinical trial execution
- Integration of AI into imaging biomarker exploration, as an additional tool to human data analyses expertise
